A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck

Cancer

Volumn 95, Issue 7, 2002, Pages 1472-1481

  Tishler, Roy B ^a   Norris Jr , Charles M ^b,c   Colevas, A Dimitrios ^b,c   Lamb, Carolyn C ^a   Karp, Daniel ^a   Busse, Paul M ^a   Nixon, Asa ^a   Frankenthaler, Robert ^a   Lake Willcutt, Bernadette ^b   Costello, Rosemary ^b,c   Case, Maryann ^b,c   Posner, Marshall R ^b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Combined modality therapy; Docetaxel; Head and neck carcinoma; Radiation

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; LARYNX EDEMA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; TRACHEOSTOMY; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0036785451     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10873     Document Type: Article

References (43)

1. Domenge C, Hill C, Lefebvre J, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer. 2000;83:1594-1598.
2. Posner M, Colevas A, Tishler R. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol. 2000;27(Suppl G):13-24.
3. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in Stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del collo. J Natl Cancer Inst. 1994;86:265-272.
4. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1689.
5. Spaulding M, Fischer S, Wolf G. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol. 1994;12:1592-1599.
6. Lefebvre J, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer Phase III trial. J Natl Cancer Inst. 1996;88(13):890-898.
7. Adelstein D, Adams G, Li Y, et al. A Phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracil (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC): an Intergroup study [abstract]. Proc Am Soc Clin Oncol. 2000;19:1624.
8. Adelstein D, Kalish L, Adams G, et al. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 1993;11:2136-2142.
9. Browman G, Cripps C, Hodson D, Eapen L, Sathya J, Levine M. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 1994;12:2648-2653.
10. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081-2086.
11. Brizel D, Albers M, Fisher S, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338: 1798-1804.
12. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16:1318-1324.
13. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:1161-1171.
14. Tishler RB, Busse PM, Norris CM, et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys. 1999;43:1001-1008.
15. Steinberg L, Hassan M, Hoppel C, et al. A Phase I study of radiotherapy and simultaneous paclitaxel in patients with locally advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 1996;15:321.
16. Sunwoo J, Herscher L, Kroog G, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol. 2001;19:800-811.
17. Rosenthal D, Lee J, Sinard R, et al. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2001;19:1363-1373.
18. Plasswilm L, Kisschner M, Sauer R. Concurent taxol and split-course accelerated radiotherapy for advanced head and neck cancer. Strahlenther Onkol. 1996;172:573-579.
19. Machtay M, Aviles V, Kligerman MM, Treat J, Weinstein GS, Weber RS. A Phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy in unresectable head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;44:311-315.
20. Hoffmann W, Belka C, Schimdberger H, Budach W, Bochtler H, Fhess CF. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer-results from a Phase I trial. Int J Radiat Oncol Biol Phys. 1997;38:691-696.
21. Hesse K, Heinreich B, Zimmerman F, Kau R, Sommer G, Achterrath W. Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors. Strahlenther Onkol. 2000;176:67-72.
22. Dowell JE, Sinard R, Yardley D, et al. Seven-week continuous infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Semin Radiat Oncol. 1999;9(Suppl 1):97-101.
23. Choy H, Akerly W, Safrin H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol. 1994;12:2682-2686.
24. Glantz M, Choy H, Kearns C, et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial radiation in adults with astrocytomas. J Clin Oncol. 1996;14:600-609.
25. Tishler R, Geard C, Hall E, Schiff P. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 1992;52:3495-3497.
26. Tishler R, Schiff P, Geard C, Hall E. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 1992;22:613-617.
27. Liebmann J, Cook J, Fisher J, Teague D, Mitchell J. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 1994;86:441-446.
28. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. 1996;56:5198-5204.
29. Mason K, Hunter N, Milas M, Abbruzzese J, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 1997;12:2431-2438.
30. Joschko M, Webster L, Groves J, Ball D, Bishop J. Radiation enhancement by taxol in squamous carcinoma of the hypopharynx (FaDu) in nude mice. Proc Am Assoc Cancer Res. 1994;35:674.
31. Mote P, Davey M, Davey R, Oliver L. Paclitaxel sensitizes multidrug resistant cells to radiation. Anticancer Drugs. 1996;7:182-188.
32. Clark J, Busse P, Norris C, et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol. 1997;15:3100-3110.
33. Colevas A, Norris C, Tishler R, et al. A Phase II trial of TPFL (docetaxel, cisplatin, 5-fluorouracil, leucovorin) as induction for squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 1999;17:3503-3511.
34. Wahl A, Donaldson K, Fairchild C, et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med. 1996;2:72-79.
35. Moos P, Fitzpatrick F. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Diff. 1998;9:687-697.
36. Milas L, Saito Y, Hunter N, Milross C, Mason K. Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. Radiother Oncol. 1996;40:163-167.
37. Hainsworth J, Burris H, Greco F. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol. 1999;26(Suppl 10):19-24.
38. Mauer A, Masters G, Haraf D, et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998;16:159-164.
39. Koukourakis M, Bahlitzanakis N, Froudarakis M, Giatromanolaki A, Georgoulias V, Koumiotaki S. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of Stage IIIB non-small-cell lung carcinoma. Br J Cancer. 1999;80:1792-1796.
40. Dreyfuss A, Clark J, Norris C, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672-1678.
41. Catimel G, Verwij J, Hanauske A. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol. 1994;5:553-537.
42. Koukourakis M, Bizakis J, Skoulakis C, Kyrmizakis D, Giatromanolaki A, Papadakis C. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A Phase I dose escalation study. Anticancer Res. 1999;19:2305-2309.
43. Fu K, Pajak T, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7-16.